HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Antithrombin Cambridge II (A384S) supports a role for antithrombin deficiency in arterial thrombosis.

Abstract
Although the control of thrombin in the microvasculature at the endothelial cell surface is crucial to prevent atherothrombosis, the role of antithrombin in arterial thrombosis is unclear. It is widely considered that antithrombin deficiency is unlikely to contribute to arterial thrombosis, but no convincing epidemiological study has been performed because of the low frequency of this deficiency. In this study we evaluated the role in myocardial infarction (MI) of a relatively common mutation affecting antithrombin gene (A384S: Antithrombin Cambridge II) that has functional features that may impair the right control of thrombogenic events caused by injury to the vascular wall. Moreover, this deficiency, which is not detected using common methods to diagnose antithrombin deficiency, also increases the risk of venous thrombosis. We included 1,224 patients with MI (691 consecutive patients and 533 survivors of a premature event), and 1,649 controls. The mutation was identified in 0.3% of controls, but 0.8% of MI patients. After adjusting for sex and other cardiovascular risk factors, the antithrombin Cambridge II significantly increased 5.66-fold the risk of MI (95% CI: 1.53-20.88; p = 0.009). Interestingly, young patients had the highest risk of MI associated with the mutation (OR: 9.98; 95%CI: 1.60-62.24; p = 0.009). This is the first epidemiological study that supports a role for antithrombin deficiency in arterial thrombosis. These results suggest that deficiency of antithrombin may be an independent risk factor for MI that has been underestimated, but larger studies are needed to confirm the relevance of inhibitors of thrombin in arterial thrombosis.
AuthorsVanessa Roldán, Adriana Ordoñez, Francisco Marín, Esther Zorio, José M Soria, Antonia Miñano, Francisco España, Rocio González-Conejero, Javier Pineda, Amparo Estellés, Jordi Fontcuberta, Vicente Vicente, Javier Corral
JournalThrombosis and haemostasis (Thromb Haemost) Vol. 101 Issue 3 Pg. 483-6 (Mar 2009) ISSN: 0340-6245 [Print] Germany
PMID19277409 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • antithrombin Cambridge II
  • Antithrombin III
Topics
  • Adult
  • Age Factors
  • Aged
  • Antithrombin III (adverse effects, genetics)
  • Antithrombin III Deficiency (complications)
  • Coronary Thrombosis (etiology)
  • Female
  • Humans
  • Male
  • Middle Aged
  • Myocardial Infarction (epidemiology, etiology, genetics)
  • Risk Factors
  • Sex Factors
  • White People

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: